Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation

Blood

Volumn 124, Issue 23, 2014, Pages 3441-3449

  Schlenk, Richard F ^a   Kayser, Sabine ^a   Bullinger, Lars ^a   Kobbe, Guido ^b   Casper, Jochen ^c   Ringhoffer, Mark ^d   Held, Gerhard ^e   Brossart, Peter ^f   Lübbert, Michael ^g   Salih, Helmut R ^h   Kindler, Thomas ⁱ   Horst, Heinz A ^j   Wulf, Gerald ^k   Nachbaur, David ^l   Götze, Katharina ^m   Lamparter, Alexander ^a   Paschka, Peter ^a   Gaidzik, Verena I ^a   Teleanu, Veronica ^a   Späth, Daniela ^a   Benner, Axel ⁿ   Krauter, Jürgen ^o   Ganser, Arnold ^o   Döhner, Hartmut ^a   Döhner, Konstanze ^a   more..

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c KLINIKUM OLDENBURG   (Germany)

^d STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

^e SAARLAND UNIVERSITY   (Germany)

^f UNIVERSITY HOSPITAL BONN   (Germany)

^g UNIVERSITY OF FREIBURG   (Germany)

^h UNIVERSITY OF TÜBINGEN   (Germany)

ⁱ JOHANNES GUTENBERG UNIVERSITY   (Germany)

^j UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^k UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^l UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^m TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁿ GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^o HANNOVER MEDICAL SCHOOL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD135 ANTIGEN; PROTEIN TYROSINE KINASE; TYROSINE KINASE DOMAIN 1; UNCLASSIFIED DRUG; FLT3 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLELE; ALLOTRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE DUPLICATION; GENE INSERTION; GENE MUTATION; HUMAN; INTERNAL TANDEM DUPLICATION; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; TREATMENT OUTCOME; CHEMISTRY; CLINICAL TRIAL; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NUCLEOTIDE SEQUENCE; PROCEDURES; PROTEIN TERTIARY STRUCTURE; STATISTICS AND NUMERICAL DATA; TANDEM REPEAT; YOUNG ADULT;

ADOLESCENT; ADULT; ALLELES; DNA MUTATIONAL ANALYSIS; FMS-LIKE TYROSINE KINASE 3; GENE DUPLICATION; GENE FREQUENCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MUTAGENESIS, INSERTIONAL; PROTEIN STRUCTURE, TERTIARY; TANDEM REPEAT SEQUENCES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84914163645     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-05-578070     Document Type: Article

References (53)

1. Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011;29(5):475-486.
2. Hayakawa F, Towatari M, Kiyoi H, et al. Tandemduplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene. 2000;19(5):624-631.
3. Mizuki M, Fenski R, Halfter H, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood. 2000;96(12): 3907-3914.
4. Brandts CH, Sargin B, Rode M, et al. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res. 2005;65(21):9643-9650.
5. Fröhling S, Schlenk RF, Breitruck J, et al; AML Study Group Ulm. Acute myeloid leukemia. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100(13):4372-4380.
6. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326-4335.
7. Schnittger S, Bacher U, Haferlach C, Alpermann T, Kern W, Haferlach T. Diversity of the juxtamembrane and TKD1 mutations (exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data. Genes Chromosomes Cancer. 2012;51(10):910-924.
8. Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. 2001;61(19):7233-7239.
9. Stirewalt DL, Kopecky KJ, Meshinchi S, et al. Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. Blood. 2006;107(9):3724-3726.
10. Meshinchi S, Stirewalt DL, Alonzo TA, et al. Structural and numerical variation of FLT3/ITD in pediatric AML. Blood. 2008;111(10):4930-4933.
11. Kusec R, Jaksic O, Ostojic S, Kardum-Skelin I, Vrhovac R, Jaksic B. More on prognostic significance of FLT3/ITD size in acute myeloid leukemia (AML). Blood. 2006;108(1):405-406, author reply 406.
12. Ponziani V, Gianfaldoni G, Mannelli F, et al. The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients. Leukemia. 2006; 20(11):2074-2076.
13. Gale RE, Green C, Allen C, et al; Medical Research Council Adult Leukaemia Working Party. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111(5):2776-2784.
14. Pratcorona M, Brunet S, Nomdedéu J, et al; Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood. 2013; 121(14):2734-2738.
15. Kayser S, Schlenk RF, Londono MC, et al; German-Austrian AML Study Group (AMLSG). Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood. 2009;114(12):2386-2392.
16. Breitenbuecher F, Schnittger S, Grundler R, et al. Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. Blood. 2009; 113(17):4074-4077.
17. Breitenbuecher F, Markova B, Kasper S, et al. A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in acute myeloid leukemia. Blood. 2009;113(17):4063-4073.
18. Schnittger S, Bacher U, Kern W, Alpermann T, Haferlach C, Haferlach T. Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia. Leukemia. 2011;25(8):1297-1304.
19. Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079-1089.
20. Gaidzik VI, Schlenk RF, Paschka P, et al. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: a comprehensive analysis of the AML Study Group (AMLSG). Blood. 2013;121(23): 4769-4777.
21. Schlenk RF, Döhner K, Krauter J, et al; German- Austrian Acute Myeloid Leukemia Study Group. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909-1918.
22. Gale RE, Hills R, Kottaridis PD, et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood. 2005; 106(10):3658-3665.
23. Bornhäuser M, Illmer T, Schaich M, Soucek S, Ehninger G, Thiede C; AML SHG 96 study group. Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML. Blood. 2007;109(5): 2264-2265, author reply 2265.
24. Labouré G, Dulucq S, Labopin M, et al. Potent graft-versus-leukemia effect after reducedintensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without FLT3-ITD. Biol Blood Marrow Transplant. 2012;18(12):1845-1850.
25. Doubek M, Muzik J, Szotkowski T, et al. Is FLT3 internal tandem duplication significant indicator for allogeneic transplantation in acute myeloid leukemia? An analysis of patients from the Czech Acute Leukemia Clinical Register (ALERT). Neoplasma. 2007;54(1):89-94.
26. Sengsayadeth SM, Jagasia M, Engelhardt BG, et al. Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers. Bone Marrow Transplant. 2012;47(12):1535-1537.
27. Brunet S, Labopin M, Esteve J, et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol. 2012;30(7):735-741.
28. DeZern AE, Sung A, Kim S, et al. Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. Biol Blood Marrow Transplant. 2011;17(9):1404-1409.
29. Schlenk RF, Benner A, Hartmann F, et al; AML Study Group Ulm (AMLSG ULM). Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial. Leukemia. 2003;17(8):1521-1528.
30. Schlenk RF, Döhner K, Mack S, et al. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol. 2010; 28(30):4642-4648.
31. Schlenk RF, Döhner K, Krauter J, et al. All-trans retinoic acid improves outcome in younger adult patients with nucleophosmin-1 mutated acute myeloid leukemia: results of the AMLSG 07-04 randomized treatment trial. Blood. 2011;118(21):80a.
32. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French- American-British Cooperative Group. Ann Intern Med. 1985;103(4):620-625.
33. Jaffe ES, Harris NL, Stein H, et al. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, 3rd ed. Lyon, France: IARC Press; 2001.
34. Mitelman F. ISCN: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: S. Karger; 1995.
35. Fröhling S, Skelin S, Liebisch C, et al; Acute Myeloid Leukemia Study Group, Ulm. Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia. J Clin Oncol. 2002; 20(10):2480-2485.
36. Schlenk RF, Taskesen E, van Norden Y, et al. The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. Blood. 2013;122(9):1576-1582.
37. Döhner H, Estey EH, Amadori S, et al; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-474.
38. Lausen B, Schumacher M. Maximally selected rank statistics. Biometrics. 1992;48:73-85.
39. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.
40. Therneau TM, Grambsch PM. Modelling Survival Data: Extending the Cox Model. New York, NY: Springer; 2000.
41. Mantel N, Byar D. Evaluation of response-time data involving transient states: An illustration using heart transplant data. J Am Stat Assoc. 1974;69(345):81-86.
42. Andersen P, Gill RD. Cox's regression model for counting processes: A large sample study. Ann Stat. 1982;10(4):1100-1120.
43. Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med. 1984;3(1):35-44.
44. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16(3):1141-1154.
45. Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer; 2001.
46. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2009.
47. Linch DC, Hills RK, Burnett AK, Khwaja A, Gale RE. Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia. Blood. 2014;124(2):273-276.
48. Stone RM, Fischer T, Paquette R, et al. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia. 2012;26(9):2061-2068.
49. Ravandi F, Cortes JE, Jones D, et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010; 28(11):1856-1862.
50. Levis M. FLT3/ITD AML and the law of unintended consequences. Blood. 2011;117(26):6987-6990.
51. Li L, Bailey E, Greenblatt S, Huso D, Small D. Loss of the wild-type allele contributes to myeloid expansion and disease aggressiveness in FLT3/ ITD knockin mice. Blood. 2011;118(18): 4935-4945.
52. Siendones E, Barbarroja N, Torres LA, et al. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors. Hematol Oncol. 2007; 25(1):30-37.
53. Knapper S, Mills KI, Gilkes AF, Austin SJ, Walsh V, Burnett AK. The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3- mutated and wild-type cases. Blood. 2006; 108(10):3494-3503.